Literature DB >> 3879752

The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt.

W H Rooks, P J Maloney, L D Shott, M E Schuler, H Sevelius, A M Strosberg, L Tanenbaum, A J Tomolonis, M B Wallach, D Waterbury.   

Abstract

Ketorolac tromethamine[(+/-)-5(benzoyl)-2,3-dihydro-1N-pyrrolizine-1-carboxylic acid tris hydroxymethylaminomethane salt] is a highly potent member of a new class of compounds having analgesic and anti-inflammatory activity. When given orally in tests involving underlying inflammation it was a potent analgesic, whereas it was inactive in tests for narcotic activity. It was also highly active orally in rat models of acute and chronic inflammation and pyresis. These properties are mediated primarily via the compound's potent prostaglandin cyclooxygenase inhibitory activity. The agent elicited mild CNS and cardiovascular activity only at doses far in excess of those required for analgesic and anti-inflammatory activity. A single 10 mg tablet given orally to human volunteers following surgery provided pain relief equivalent to that provided by 10 mg of morphine given intramuscularly. When given intramuscularly to rabbits (0.25 ml of a 0.31-5% solution) or man (3 ml of a 1-3% solution), no drug-related irritation or changes in creatine phosphokinase were seen. Solutions (less than or equal to 0.5%) applied to the eyes of animals and man were not irritating. When applied topically in rat and rabbit models of ocular inflammation, less than or equal to 0.5% solutions of ketorolac tromethamine inhibited the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3879752

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  21 in total

1.  The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation.

Authors:  H J Park; K Sandor; J McQueen; S A Woller; C I Svensson; M Corr; T L Yaksh
Journal:  Eur J Pain       Date:  2015-10-30       Impact factor: 3.931

Review 2.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

3.  Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine.

Authors:  D Jung; E J Mroszczak; A Wu; T L Ling; H Sevelius; L Bynum
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

4.  A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs.

Authors:  K A Mathews; D M Paley; R A Foster; A E Valliant; S S Young
Journal:  Can Vet J       Date:  1996-09       Impact factor: 1.008

5.  Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.

Authors:  D Jung; E Mroszczak; L Bynum
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Ketorolac (Toradol): a new analgesic or an old NSAID?

Authors:  W Spickler
Journal:  CMAJ       Date:  1993-05-15       Impact factor: 8.262

7.  Ketorolac (Toradol): a marketing phenomenon.

Authors:  R E Ariano; S A Zelenitsky
Journal:  CMAJ       Date:  1993-05-15       Impact factor: 8.262

Review 8.  Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.

Authors:  Bruce I Gaynes; Richard Fiscella
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

10.  Lack of activity of ketorolac in hot-plate test and serotonin binding capacity of brain membranes in rats.

Authors:  G Vitale; M Sandrini; L A Pini
Journal:  Agents Actions       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.